Navigation Links
3SBio Inc. Announces SFDA Approval of High-Dose EPIAO
Date:7/11/2011

SHENYANG, China, July 11, 2011 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that the Chinese State Food and Drug Administration ("SFDA") has approved its 36,000 IU dosage formulation of EPIAO for the treatment of anemia associated with chemotherapy in cancer patients. High-dose EPIAO is the only dosage form of this kind available in China. The approval provides patients in China with an additional treatment option which has been available since 2004 in the United States and 2006 in the United Kingdom.

High-dose EPIAO is designed for the rapid restoration of hemoglobin to normal levels among cancer patients. The 36,000 IU dosage is comparable to the standardized dose used globally for chemotherapy-induced anemia, allowing for less frequent administration than lower dosage forms, which in turn is expected to provide greater convenience for both patients and caregivers.  

The clinical trial examined the safety and efficacy of a weekly subcutaneous injection of 36,000 IU EPIAO in oncology patients compared with a regimen of three times per week administration of 10,000 IU EPIAO. The results showed that 70% of the patients receiving high-dose EPIAO injections had hemoglobin improvement of 1-2 g/dL from baseline, similar to those receiving three times per week dosing of 10,000 IU EPIAO. More importantly, the weekly administration of 36,000 IU EPIAO demonstrated equivalent safety and tolerability profiles as the three times per week 10,000 IU EPIAO.

Commenting on the news, Dr. Jing Lou, chief executive officer of 3SBio, said: "Our new 36,000 IU formulation of EPIAO is the highest dose EPO formulation on the market in China, and EPIAO remains the only EPO product approved in
'/>"/>

SOURCE 3SBio Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. 3SBio Announces Conversion of Isotechnika Debenture
2. 3SBio Inc. Schedules Third Quarter 2010 Unaudited Financial Results
3. 3SBio Announces Partial Conversion of Isotechnika Debenture
4. 3SBio Announces Investor Conference Schedule
5. 3SBio and Isotechnika Pharma Announce Strategic Partnership to Develop and Commercialize Voclosporin in China
6. 3SBio Inc. Announces Results of Annual General Meeting
7. Surgical Care Affiliates Announces Agreement With Suburban Outpatient Surgery Center
8. Pinnaclife Announces Prenatal Nutrition Package and Mother Baby Skin Care Line
9. Metamark Genetics Announces Cancer Cell Study Highlighting Discovery of Key Molecules that Drive Progression of Malignant Melanoma in Humans
10. Vycor Medical, Inc. Announces Alvaro Pascual-Leone, MD, PhD as Head of the Strategic Advisory Board of its NovaVision, Inc. Subsidiary
11. Patient Advocate Foundation Announces Significant Operational, Technology Enhancements to Co-Pay Relief (CPR) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... -- Biosensors International Group, Ltd. ("Biosensors" or the ... a developer, manufacturer and marketer of innovative medical ... fiscal quarter ended 30 June 2015 ("Q1 FY16"). ... , Biosensors continued to make ... by lower operating expenses and operational improvement. Operating ...
(Date:8/3/2015)... , Aug. 3, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... host its Second Quarter 2015 Investor Conference Call and ... The call will cover an update on ... quarter 2015 financials. A press release detailing the information ... the afternoon of Monday, August 10. Investors and the ...
(Date:8/3/2015)... , Aug. 3, 2015  Charleston Laboratories, Inc., ... its second clinical development program with a Phase ... CL-H1T contains fast-dissolving promethazine and ... as a treatment for migraine headache pain and ... "Many patients with migraine headaches also suffer from ...
Breaking Medicine Technology:Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2
... 2011 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China ... CSKI ), a leading fully integrated pharmaceutical company in ... shareholder letter from Mr. Yanqing Liu, the Company,s Chairman ... full text of this shareholder letter is as follows: ...
... 21, 2011 VIVUS, Inc. (Nasdaq: VVUS ) ... Food and Drug Administration (FDA) for the New Drug Application ... obesity.  The meeting occurred on January 19th at the FDA,s ... the FDA and VIVUS, management and consultants.  At this meeting ...
Cached Medicine Technology:Shareholder Letter from Chairman of China Sky One Medical 2Shareholder Letter from Chairman of China Sky One Medical 3Shareholder Letter from Chairman of China Sky One Medical 4VIVUS Provides Regulatory Update on QNEXA NDA 2VIVUS Provides Regulatory Update on QNEXA NDA 3
(Date:8/3/2015)... ... August 03, 2015 , ... Dental practice in Los ... in need. Most people know that general health emergencies, such as broken arms or ... of people know where to turn to during a dental emergency. This is important, ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... Physician Leadership ® and Navigant Center for Healthcare Research and Policy Analysis show ... Fifty-five percent of respondents said they agreed or strongly agreed that the controversial ...
(Date:8/3/2015)... ... August 03, 2015 , ... The U.S. Food and Drug Administration (FDA) ... similar to deoxycholic acid, which occurs naturally in the body and helps absorb and ... this area of the body. These are invasive procedures and very expensive for most ...
(Date:8/3/2015)... ... 2015 , ... Illinois Health & Science (IHS) has completed the purchase of ... all of IBAM NA’s cyclotron sites and research and development facilities. , ... as well as a large manufacturing hub in Noblesville, Indiana,” said Ken Smithmier, President ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... Government Programs, with accountability for overall performance of the company’s Medicare and Federal ... focus of Cambia’s strategy to deliver better health for members. In this role, ...
Breaking Medicine News(10 mins):Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:Cambia Health Solutions Names Scott Powers President of Government Programs 2
... chapping, experts advise , SATURDAY, Dec. 26 (HealthDay News) ... humidity, and the air inside is heated and dry, you ... say. , To prevent scaling, flaking and itching, pay special ... a cream-based moisturizer every day, recommends Dr. Anjali Dahiya, a ...
... Christmas trees and holiday distractions raise risk of a blaze ... on beautifully set tables and yule logs burning make for ... the risk of fires, experts say. , Alcohol and parties ... safety, said Dr. Roger Yurt, director of the Hearst Burn ...
... to those in pot that increase the response to sweets ... some light on the "munchies" -- the desire that pot ... the active ingredient in marijuana, is similar to substances known ... and enhance the perception of sweet foods, researchers say. , ...
... Mouse study holds promise for humans with hereditary disease ... reporting that they,ve discovered a molecular switch that appears ... in mice. , An estimated one out of every ... and disrupts a person,s ability to walk, talk, think ...
... , WASHINGTON, Dec. 24 This ... final passage of HR 3590, the so-called "Patient Protection and ... Research Council President Tony Perkins made the following comments: , ... debate in the Senate, but it,s far from the end ...
... Bill Must Be Improved: Anti-Choice Provisions in Senate and House ... Affordable , WASHINGTON, Dec. 24 The following ... for Women & Families: , "The Senate took a historic ... morning by passing comprehensive reform that will cover 31 million ...
Cached Medicine News:Health News:Skin Needs Protection From Winter Weather 2Health News:Keep Fire Safety in Mind as You Celebrate 2Health News:Scientists Find Molecular Switch Related to Huntington's 2Health News:FRC Statement on the Christmas Eve Passage of the Health Care 'Reform' Bill 2Health News:Senate Passage of Health Reform a Historic Milestone, National Partnership President Says 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: